A Phase I/II Study of an Oral Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor (EGFR-TKI), ZD 1839 (Iressa), [NSC 715055] With Radiation Therapy in Glioblastoma Multiforme
Phase of Trial: Phase I/II
Latest Information Update: 12 Jun 2013
At a glance
- Drugs Gefitinib (Primary)
- Indications Glioblastoma
- Focus Adverse reactions; Therapeutic Use
- 31 Aug 2018 Biomarkers information updated
- 25 Apr 2012 Actual end date (Jan 2012) added as reported by ClinicalTrials.gov.
- 25 Apr 2012 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.